pharmaceuticals

pharmaceuticals Articles

The 2017 annual meeting of the American Society of Clinical Oncology (ASCO) runs from June 2 to June 6. The following companies have signaled that they will be presenting data, or data will be...
MEI Pharma, Inc. (NASDAQ: MEIP) saw its shares make a solid gain on Thursday after the company received a crucial upgrade from Oppenheimer. Most analysts only issue price targets that are within...
A new Deutsche Bank research report focuses on the big capitalization pharmaceutical stocks and the upcoming catalysts and news flow they have for the rest of 2017.
The May 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mostly upward.
24/7 Wall St. takes a look at Eli Lilly, and what Credit Suisse sees happening for this pharma giant at ASCO.
Shares of Inovio Pharmaceuticals saw a massive gain early on Wednesday after the company announced a critical update from its HIV vaccine.
Credit Suisse comments on Merck ahead of the American Society of Clinical Oncology (ASCO) conference.
Syndax Pharmaceuticals has announced that Encore 601 has met the prespecified objective response threshold to advance into the second stage of the Phase 2 trial and will reopen enrollment immediately.
Akebia Therapeutics saw its shares hit a new 52-week high in Tuesday’s session following a key licensing agreement with Vifor Pharma.
Athenex has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Pantheon shares saw a huge gain on Monday following the announcement that the company will be acquired by Thermo Fisher Scientific.
Ionis Pharmaceuticals saw its shares pullback on Monday morning after results were released from its late-stage trial for the treatment of familial amyloid polyneuropathy.
The WHO has confirmed a new outbreak of the Ebola virus in the Democratic Republic of Congo. A few of the Ebola-related stocks are responding.
G1 Therapeutics expects to offer more than 6 million shares in the range of $15 to $17 apiece in an initial public offering valued up to around $122 million.
With prescription drug spending breaking new records almost every year now, people like to blame Big Pharma and use it as the industry punching bag.